Functions of invariant NK T cells are modulated by TLR ligands and IFN-α

Innate Immunity

Volumn 21, Issue 3, 2015, Pages 275-288

  Villanueva, A Ian ^a   Haeryfar, SM Mansour ^b   Mallard, Bonnie A ^a   Kulkarni, Raveendra R ^c   Sharif, Shayan ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiviral; CpG; IFN ; iNKT cell; macrophage; TLR

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD1D ANTIGEN; GAMMA INTERFERON; GLYCOLIPID; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MONOCLONAL ANTIBODY; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; CULTURE MEDIUM; CYTOKINE; LIGAND;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FIBROBLAST; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; INVARIANT NATURAL KILLER T CELL; MACROPHAGE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; SUPERNATANT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VESICULOVIRUS; VIRUS REPLICATION; AGONISTS; ANIMAL; CELL LINE; CULTURE MEDIUM; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHARMACOLOGY; PHYSIOLOGY; RHABDOVIRUS INFECTION; SECRETION (PROCESS); VIROLOGY;

MUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; CELL LINE; CULTURE MEDIA, CONDITIONED; CYTOKINES; FIBROBLASTS; INTERFERON-ALPHA; LIGANDS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; NATURAL KILLER T-CELLS; RHABDOVIRIDAE INFECTIONS; TOLL-LIKE RECEPTORS; VESICULOVIRUS; VIRUS REPLICATION;

EID: 84924764845     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425914527327     Document Type: Article

References (51)

1. Dellabona P, Padovan E, Casorati G, et al. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med. 1994; 180: 1171-1176
2. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med. 1994; 180: 1097-1106
3. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997; 278: 1626-1629
4. Kulkarni R, Villanueva AI, Elawadli I, et al. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists. Cell Immunol. 2012; 277: 33-43
5. Moreno M, Mol BM, von Mensdorff-Pouilly S, et al. Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists. Immunotherapy. 2009; 1: 557-570
6. Gardner TR, Chen Q, Jin Y, Ajuebor MN. Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha 14 invariant natural killer T cells to negatively regulate gammadeltaT cells. Am J Pathol. 2010; 176: 1779-1789
7. Kim JH, Kim HS, Kim HY, et al. Direct engagement of TLR4 in invariant NKT cells regulates immune diseases by differential IL-4 and IFN-γ production in mice. PloS One. 2012; 7: e45348 - e45348
8. Paget C, Bialecki E, Fontaine J, et al. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides. J Immunol. 2009; 182: 1846-1853
9. Tyznik AJ, Tupin E, Nagarajan NA, et al. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol. 2008; 181: 4452-4456
10. Moody DB. TLR gateways to CD1 function. Nat Immunol. 2006; 7: 811-817
11. Hermans IF, Silk JD, Gileadi U, et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol. 2007; 178: 2721-2729
12. Tanaka S, Koizumi S, Masuko K, et al. Toll-like receptor-dependent IL-12 production by dendritic cells is required for activation of natural killer cell-mediated Type-1 immunity induced by Chrysanthemum coronarium L. Int Immunopharmacol. 2011; 11: 226-232
13. Leite-de-Moraes MC, Hameg A, Arnould A, et al. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J Immunol. 1999; 163: 5871-5876
14. Uchida T, Kinoshita M, Fukasawa M, et al. IL-18 time-dependently modulates Th1/Th2 cytokine production by ligand-activated NKT cells. Eur J Immunol. 2007; 37: 966-977
15. Akira S, Tokeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2: 675-680
16. Komai-Koma M, Jones L, Ogg GS, et al. TLR2 is expressed on activated T cells as a costimulatory receptor. PNAS. 2004; 101: 3029-3034
17. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. PNAS. 2006; 103: 7048-7053
18. LaRosa DF, Stumhofer JS, Gelman AE, et al. T cell expression of MyD88 is required for resistance to Toxoplasma gondii. PNAS. 2008; 105: 3855-3860
19. LaRosa DF, Gelman AE, Rahman AH, et al. CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett. 2007; 108: 183-188
20. Wesch D, Beetz S, Oberg H-H, et al. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol. 2006; 176: 1348-1354
21. Wesch D, Peters C, Oberg H-H, et al. Modulation of gammadelta T cell responses by TLR ligands. Cell Mol Life Sci. 2011; 68: 2357-2370
22. Oberg H-H, Juricke M, Kabelitz D, Wesch D. Regulation of T cell activation by TLR ligands. Eur J Cell Biol. 2011; 90: 582-592
23. Oberg H-H, Ly TTH, Ussat S, et al. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J Immunol. 2010; 184: 4733-4740
24. Salem ML, Diaz-Montero CM, El-Naggar SA, et al. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their Ag-specific responses upon their adoptive transfer into naïve recipient mice. Vaccine. 2009; 27: 549-557
25. Thompson LJ, Kolumam GA, Thomas S, Murali-krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol. 2013; 177: 1746-1754
26. Paget C, Mallevaey T, Speak AO, et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity. 2007; 27: 597-609
27. Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol. 2012; 90: 492-497
28. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004; 172: 6065-6073
29. Imanishi T, Hara H, Suzuki S, et al. Cutting edge: TLR2 directly triggers Th1 effector functions. J Immunol. 2007; 178: 6715-6719
30. Gelman AE, LaRosa DF, Zhang J, et al. The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity. 2006; 25: 783-793
31. Xu D, Komai-Koma M, Liew FY. Expression and function of Toll-like receptor on T cells. Cell Immunol. 2005; 233: 85-89
32. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006; 7: 131-137
33. Burdin N, Brossay L, Koezuka Y, et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates Valpha14+ NK T lymphocytes. J Immunol. 1998; 161: 3271-3281
34. Boudreau JE, Bridle BW, Stephenson KB, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther. 2009; 17: 1465-1472
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: 2002-2007
36. Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun. 12: 218-234
37. Sandor M, Lynch RG. Lymphocyte Fc receptors: the special case of T cells. Immunol Today. 1993; 14: 227-231
38. Bachwich PR, Chensue SW, Larrick JW, Kunkel SL. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Bioph Res Commun. 1986; 136: 94-101
39. Mosser DM. The many faces of macrophage activation. J Leukocyte Biol. 2003; 73: 209-212
40. Kulkarni R, Haeryfar SM, Sharif S. The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity?. J Leukocyte Biol. 2010; 88: 635-643
41. Berzins SP, Smyth MJ, Godfrey DI. Working with NKT cells - pitfalls and practicalities. Curr Opin Immunol. 2005; 17: 448-454
42. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011; 17: 2619-2627
43. Stevens CN, Simeone A-M, John S, et al. T-cell receptor early signalling complex activation in response to interferon-alpha receptor stimulation. Biochem J. 2010; 428: 429-437
44. Marschner A, Rothenfusser S, Hornung V, et al. CpG ODN enhance Ag-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol. 2005; 35: 2347-2357
45. Murray H, Spitalny G, Nathan C. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol. 1985; 134: 1619-1622
46. Reed S. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol. 1988; 140: 4342-4347
47. Flynn JL, Chan J, Triebold KJ, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993; 178: 2249-2254
48. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the "Swiss-Army knife" of the immune system. Curr Opin Immunol. 2008; 20: 358-368
49. Wahl C, Bochtler P, Schirmbeck R, Reimann J. Type I IFN-producing CD4 Valpha14i NKT cells facilitate priming of IL-10-producing CD8 T cells by hepatocytes. J Immunol. 2007; 178: 2083-2093
50. Seo S, Webster R. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol. 2002; 76: 1071-1076
51. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol. 2007; 81: 7351-7362